Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on … – GlobeNewswire (press release)
|
Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on …
GlobeNewswire (press release) BERKELEY, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that its license partner, Janssen Biotech, Inc., presented a poster … |
